Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ELAB
ELAB logo

ELAB Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.190
Open
1.180
VWAP
1.17
Vol
1.15M
Mkt Cap
6.09M
Low
1.140
Amount
1.35M
EV/EBITDA(TTM)
--
Total Shares
4.54M
EV
-3.27M
EV/OCF(TTM)
--
P/S(TTM)
--
PMGC Holdings Inc. is a diversified holding company. Its operating companies include Northstrive Biosciences Inc., PMGC Capital LLC, Pacific Sun Packaging, Inc., ELAB Opportunity Holdings LLC, SVM Machining, Inc., NorthStrive Defense Tech LLC and A&B Aerospace, Inc. Northstrive Biosciences Inc. is a biopharmaceutical company focusing on development and acquisition of aesthetic medicines and therapeutic products. PMGC Capital LLC is a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. Pacific Sun Packaging, Inc. is a specialty packaging provider focused on high-precision, component-level packaging solutions for the electronics and information technology hardware industries. NorthStrive Defense Tech LLC is focused on defense technology, including drone technology, autonomous systems, and next-generation unmanned defense solutions.
Show More

Events Timeline

(ET)
2026-07-06
08:00:00
PMGC Merges AGA Precision Systems into A&B Aerospace
select
2026-06-18 (ET)
2026-06-18
08:00:00
PMGC Holdings Files New Patent Applications Expanding EL-22 and EL-32
select
2026-06-01 (ET)
2026-06-01
07:40:00
PMGC Plans to Acquire 76% Controlling Interest in Arizona Company
select
2026-05-13 (ET)
2026-05-13
05:20:00
PMGC Acquires A&B Aerospace
select
2026-04-21 (ET)
2026-04-21
07:40:00
PMGC Holdings Subsidiary SVM Signs Long-Term Agreement with Turbo-Jet Products
select
2026-04-02 (ET)
2026-04-02
17:20:00
PMGC Launches Wholly Owned Subsidiary NorthStrive Defense Tech
select
2026-04-01 (ET)
2026-04-01
10:10:00
PMGC Holdings Inc Trading Halted Due to Volatility
select
2026-03-27 (ET)
2026-03-27
16:10:00
PMGC Holdings' Subsidiary Amends Agreement with MOA Life Plus
select
2026-03-24 (ET)
2026-03-24
07:20:00
PMGC Holdings Completes ITAR Registration, Enhances SVM's Supplier Qualification
select

News

Newsfilter
8.5
07-06Newsfilter
PinnedPMGC Merges AGA Precision into A&B Aerospace to Streamline Operations
  • Strategic Merger: PMGC Holdings announced the merger of AGA Precision Systems into A&B Aerospace, aiming to streamline its aerospace precision manufacturing platform by consolidating two related businesses, thereby enhancing operational efficiency and resource sharing.
  • Continued Operations: Post-merger, AGA will cease to exist as a separate legal entity, while A&B Aerospace will continue to operate under the AGA name to maintain customer and contract continuity, ensuring that customer relationships remain intact.
  • Resource Sharing: Both manufacturing sites are expected to continue operations, with the combined business sharing personnel, facilities, and equipment, which is anticipated to reduce duplicative governance and administrative overhead, enhancing overall operational flexibility.
  • Enhanced Customer Coverage: PMGC expects the combined structure to support greater customer coverage and service capabilities, further solidifying its market position in the aerospace and defense sectors.
Newsfilter
9.5
07-01Newsfilter
Emerging Biotech Firms Show Significant Clinical Progress
  • Can-Fite Clinical Results: Can-Fite BioPharma's Phase 2a study with 20 patients achieved its primary safety endpoint, showing a median overall survival exceeding five months in heavily pretreated patients, which is expected to propel the company into a Phase 2b combination study with chemotherapy to further validate efficacy.
  • NeOnc Regulatory Progress: NeOnc Technologies is set to release Phase 2a data from its NEO100-01 study, which has received multiple FDA designations, providing significant regulatory advantages, while its recent IND approval in Abu Dhabi will expand its international clinical trial scope.
  • PMGC AI Drug Discovery: PMGC Holdings' NorthStrive Biosciences partnership with Yuva Biosciences has identified several small-molecule candidates using the MitoNova™ AI platform, demonstrating potential muscle health benefits, which is expected to advance its EL-22 program further.
  • Market Focus: Biotechnology investors are gravitating towards companies capable of generating multiple value-driving catalysts, with Can-Fite, NeOnc, and PMGC's upcoming clinical data, regulatory milestones, and AI drug discovery advancements indicating a critical observation period in the coming months.
Newsfilter
8.5
07-01Newsfilter
Yuva Biosciences' AI Platform Achieves Breakthrough in Drug Discovery
  • Significant AI Achievements: Yuva Biosciences' MitoNova™ AI platform successfully identified four small-molecule candidates that significantly increased ANT1 protein expression in primary human skeletal muscle cells, indicating their potential role in muscle energy metabolism and offering new therapeutic avenues for muscle health and metabolic stress applications.
  • Outstanding Candidate Performance: In the Phase III study, candidates C1, C2, C3, and C4 demonstrated statistically significant increases in ANT1 expression, with C2 showing a 50% increase, C4 at 48%, C1 at 46%, and C3 achieving a 29% increase at the highest dose, highlighting their promising dose-dependent effects.
  • Next Development Steps: Following the positive Phase III results, Yuva Biosciences recommended advancing the four validated candidates into a more mature skeletal muscle model for confirmatory testing, aiming to further validate ANT1 induction and mitigate risks in subsequent development, reflecting the company's confidence in future product advancements.
  • Deepening Strategic Collaboration: The study results not only validate Yuva Biosciences' AI-driven drug discovery capabilities but also provide crucial support for NorthStrive Biosciences' muscle preservation development strategy, signaling potential market opportunities in aging-related therapies.
Newsfilter
8.5
06-18Newsfilter
PMGC Files New Patents for Muscle Preservation in Weight Loss Treatments
  • Patent Application Expansion: PMGC Holdings' wholly-owned subsidiary NorthStrive has filed two new patent applications for human pharmaceutical uses of EL-22 and EL-32 aimed at preserving lean muscle mass during GLP-1 and obesity-related weight loss, marking a strategic shift from animal health to human applications.
  • New Drug Combinations: The new applications include the co-administration of EL-22 or EL-32 with apelin or ursolic acid, compounds associated with muscle support, addressing the growing demand in the obesity treatment market and potentially opening new revenue streams for the company.
  • Market Demand Response: With the rapid adoption of GLP-1 and related weight loss therapies, PMGC believes that the need for muscle preservation will become a critical area of product development, enhancing the company's competitiveness in the biopharmaceutical market.
  • Technological Innovation: The new patent applications encompass various pharmaceutical delivery forms, including oral, injectable, and topical, showcasing the company's innovative capabilities in muscle preservation, which is expected to lay the groundwork for future clinical applications.
Newsfilter
7.5
06-10Newsfilter
PMGC Positions Precision Manufacturing Platform for Space Economy Growth
  • Growing Market Demand: PMGC's subsidiaries A&B Aerospace, SVM Machining, and AGA Precision Systems are leveraging advanced precision manufacturing capabilities to meet the rapidly expanding space economy, with projections indicating the global space economy could reach $1.8 trillion by 2035, highlighting significant market potential.
  • Technical Certification Advantage: These companies possess ITAR registration and AS9100 certification, ensuring their products meet high standards required in aerospace and defense sectors, thereby enhancing their competitiveness in space exploration and related markets.
  • Established Customer Base: Prior to acquisition, PMGC's operating companies had built strong relationships with notable clients such as SpaceX and Moog, with space-related projects accounting for 5.7% of total revenue over the past two years, laying a solid foundation for future growth.
  • Significant Growth Opportunities: PMGC plans to expand its market share in space exploration, satellite, and launch systems by leveraging existing operating companies and technical expertise, capitalizing on largely untapped market opportunities to drive long-term growth.
Newsfilter
7.5
06-08Newsfilter
NorthStrive Defense Tech Signs Patent Licensing Agreement
  • Patent Licensing Agreement: NorthStrive Defense Tech has entered into a binding patent licensing agreement covering U.S. Patent No. 12,291,334 for multi-domain drone payload technology, aimed at enhancing transport efficiency in the aerospace and defense sectors, which is expected to bolster the company's competitive position in the relevant markets.
  • Technological Advantage: This technology enables drones to autonomously transport cable-suspended payloads across air and water, utilizing buoyancy-assisted transport to significantly improve payload efficiency over traditional air-only drone systems, addressing the need for concealed transport in complex maritime environments.
  • R&D Plan: The accompanying sponsored research program will last for 12 months, focusing on developing a small payload prototype and conducting empirical testing to ensure the feasibility and stability of the technology, thereby laying the groundwork for future commercialization and advancing the company's growth in the defense market.
  • Market Outlook: With advancements in unmanned undersea vehicle technology by the U.S., U.K., and Australia, NorthStrive Defense Tech believes its patented technology is well-positioned in a defense market increasingly focused on multi-domain unmanned systems and maritime autonomy, potentially leading to more commercial opportunities in the future.

Valuation Metrics

The current forward P/E ratio for PMGC Holdings Inc (ELAB.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess PMGC Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

I need all stocks that about to halt?
Intellectia · 22 candidates
Price Change Pct: $-100.00 - $-8.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASENews Driver: Positive, Negative
Ticker
Name
Market Cap$
top bottom
ITRM logo
ITRM
Iterum Therapeutics PLC
1.90M
BUR logo
BUR
Burford Capital Ltd
906.24M
LTRN logo
LTRN
Lantern Pharma Inc
12.53M
ONCO logo
ONCO
Onconetix Inc
1.35M
AMPG logo
AMPG
Amplitech Group Inc
45.60M
SLND logo
SLND
Southland Holdings Inc
66.02M
stocks under 10 expected to gap up today
Intellectia · 26 candidates
Price: $1.00 - $10.00Volume: >= 200,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEGap Pattern: GapUpPre Market Price Change: >= $3.00
Ticker
Name
Market Cap$
top bottom
JZXN logo
JZXN
Jiuzi Holdings Inc
1.66M
CDIO logo
CDIO
Cardio Diagnostics Holdings Inc
3.89M
BOXL logo
BOXL
Boxlight Corp
1.24M
TALK logo
TALK
Talkspace Inc
651.03M
ELAB logo
ELAB
PMGC Holdings Inc
1.46M
MOB logo
MOB
Mobilicom Ltd
58.61M

Whales Holding ELAB

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is PMGC Holdings Inc (ELAB) stock price today?

The current price of ELAB is 1.19 USD — it has decreased -11.19

What is PMGC Holdings Inc (ELAB)'s business?

PMGC Holdings Inc. is a diversified holding company. Its operating companies include Northstrive Biosciences Inc., PMGC Capital LLC, Pacific Sun Packaging, Inc., ELAB Opportunity Holdings LLC, SVM Machining, Inc., NorthStrive Defense Tech LLC and A&B Aerospace, Inc. Northstrive Biosciences Inc. is a biopharmaceutical company focusing on development and acquisition of aesthetic medicines and therapeutic products. PMGC Capital LLC is a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. Pacific Sun Packaging, Inc. is a specialty packaging provider focused on high-precision, component-level packaging solutions for the electronics and information technology hardware industries. NorthStrive Defense Tech LLC is focused on defense technology, including drone technology, autonomous systems, and next-generation unmanned defense solutions.

What is the price predicton of ELAB Stock?

Wall Street analysts forecast ELAB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELAB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is PMGC Holdings Inc (ELAB)'s revenue for the last quarter?

PMGC Holdings Inc revenue for the last quarter amounts to 681.99K USD, decreased

What is PMGC Holdings Inc (ELAB)'s earnings per share (EPS) for the last quarter?

PMGC Holdings Inc. EPS for the last quarter amounts to -11.17 USD, decreased -95.50

How many employees does PMGC Holdings Inc (ELAB). have?

PMGC Holdings Inc (ELAB) has 32 emplpoyees as of July 08 2026.

What is PMGC Holdings Inc (ELAB) market cap?

Today ELAB has the market capitalization of 6.09M USD.